Role of Nox2 in diabetic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 7, 2013, Pages

  You, Young Hyun ^a,b   Okada, Shinichi ^a,b   Ly, San ^a,b   Jandeleit Dahm, Karin ^c   Barit, David ^c   Namikoshi, Tamehachi ^c   Sharma, Kumar ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Albuminuria; Matrix; NADPH oxidase; Nephropathy; Nox2; Nox4; Oxidative stress

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; CCL2 PROTEIN, MOUSE; COLLAGEN TYPE 4; CYBB PROTEIN, MOUSE; FIBRONECTIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NOX4 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ALBUMINURIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CREATININE CLEARANCE; GENE EXPRESSION; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FUNCTION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SUBUNIT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; CHEMOKINE CCL2; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FIBRONECTINS; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; NADPH OXIDASE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

MLCS; MLOWN;

EID: 84878252198     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00511.2012     Document Type: Article

References (36)

1. Babelova A, Avaniadi D, Jung O, Fork C, Beckmann J, Kosowski J, Weissmann N, Anilkumar N, Shah AM, Schaefer L, Schroder K, Brandes RP. Role of Nox4 in murine models of kidney disease. Free Radic Biol Med 53: 842-853, 2012.
2. Breyer M, Bottinger E, Brosius Fr Coffman T, Harris R, Heilig C, Sharma KA. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005.
3. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 21: 2399-2405, 2006.
4. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8: 691-728, 2006.
5. Cheng G, Cao Z, Xu X, van Meir EG, Lambeth JD. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 269: 131-140, 2001.
6. Cohen MP, Sharma K, Guo J, Eltayeb BO, Ziyadeh FN. The renal TGF-beta system in the db/db mouse model of diabetic nephropathy. Exp Nephrol 6: 226-233, 1998.
7. Cotter MA, Cameron NE. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 73: 1813-1824, 2003.
8. De Deken X, Wang D, Many MC, Costagliola S, Libert F, Vassart G, Dumont JE, Miot F. Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem 275: 23227-23233, 2000.
9. Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, Wo-jnowski L. Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med 42: 466-473, 2007.
10. Ding H, Hashem M, Triggle C. Increased oxidative stress in the strep-tozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS. Eur J Pharmacol 561: 121-128, 2007.
11. Dupuy C, Ohayon R, Valent A, Noel-Hudson MS, Deme D, Virion A. Purification of a novel flavoprotein involved in the thyroid NADPH oxidase. Cloning of the porcine and human cDNAs. J Biol Chem 274: 37265-37269, 1999.
12. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, Nawata H. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabe-tologia 46: 1428-1437, 2003.
13. Geiszt M. NADPH oxidases: new kids on the block. Cardiovasc Res 71: 289-299, 2006.
14. Giunti S, Calkin AC, Forbes JM, Allen TJ, Thomas MC, Cooper ME, Jandeleit-Dahm KA. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am J Physiol Renal Physiol 299: F528-F535, 2010.
15. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280: 39616-39626, 2005.
16. Gorlach A, Brandes RP, Bassus S, Kronemann N, Kirchmaier CM, Busse R, Schini-Kerth VB. Oxidative stress and expression of p22phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets. FASEB J 14: 1518-1528, 2000.
17. Hebden RA, Bennett T, Gardiner SM. Pressor sensitivities to vasopressin, angiotensin II, or methoxamine in diabetic rats. Am J Physiol Regul Integr Comp Physiol 253: R726-R734, 1987.
18. Hilenski L, Clempus R, Quinn M, Lambeth JD, Greindling K. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24: 1-8, 2004.
19. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14: S227-S232, 2003.
20. Liu JQ, Zelko IN, Erbynn EM, Sham JS, Folz RJ. Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). Am J Physiol Lung Cell Mol Physiol 290: L2-L10, 2006.
21. Lo W, Bravo T, Jadhav V, Titova E, Zhang JH, Tang J. NADPH oxidase inhibition improves neurological outcomes in surgically-induced brain injury. Neurosci Lett 414: 228-232, 2007.
22. Murdoch CE, Alom-Ruiz SP, Wang M, Zhang M, Walker S, Yu B, Brewer A, Shah AM. Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res Cardiol 106: 527-538, 2011.
23. Nlandu Khodo S, Dizin E, Sossauer G, Szanto I, Martin PY, Feraille E, Krause KH, de Seigneux S. NADPH-Oxidase 4 Protects against Kidney Fibrosis during Chronic Renal Injury. J Am Soc Nephrol 23: 1967-1976, 2012.
24. Pendyala S, Gorshkova IA, Usatyuk PV, He D, Pennathur A, Lambeth JD, Thannickal VJ, Natarajan V. Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells. Antioxid Redox Signal 11: 747-764, 2009.
25. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superox-ide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288: F1144-F1152, 2005.
26. Satriano JA, Shuldiner M, Hora K, Xing Y, Shan Z, Schlondorff D. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immuno-globulin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J Clin Invest 92: 1564-1571, 1993.
27. Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewiez C, Page P, Kennedy CR, Burns KD, Touyz RM, Hebert RL. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 299: F1348-F1358, 2010.
28. Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, and Touyz RM. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) 124: 191-202, 2013.
29. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Forro L, Schlegel W, Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 406: 105-114, 2007.
30. Seyer-Hansen K, Hansen J, Gundersen HJ. Renal hypertrophy in experimental diabetes. A morphometric study. Diabetologia 18: 501-505, 1980.
31. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645-1656, 2008.
32. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233, 2006.
33. Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G, Gambino R, Vergola D, Pinach S, Perin PC, Camussi G, Gruden G. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 58: 2109-2118, 2009.
34. Tomlinson KC, Gardiner SM, Bennett T. Blood pressure in streptozotocin-treated Brattleboro and Long-Evans rats. Am J Physiol Regul Integr Comp Physiol 258: R852-R859, 1990.
35. Williams KJ, Qiu G, Usui HK, Dunn SR, McCue P, Bottinger E, Iozzo RV, Sharma K. Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol 171: 1441-1450, 2007.
36. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 76: 32-43, 2009.